ATE432926T1 - Oxazolderivate als histamin-h3-rezeptor- wirkstoffe, deren herstellung und therapeutische verwendung - Google Patents

Oxazolderivate als histamin-h3-rezeptor- wirkstoffe, deren herstellung und therapeutische verwendung

Info

Publication number
ATE432926T1
ATE432926T1 AT05773290T AT05773290T ATE432926T1 AT E432926 T1 ATE432926 T1 AT E432926T1 AT 05773290 T AT05773290 T AT 05773290T AT 05773290 T AT05773290 T AT 05773290T AT E432926 T1 ATE432926 T1 AT E432926T1
Authority
AT
Austria
Prior art keywords
histamine
nitrogen
formula
ring
compounds
Prior art date
Application number
AT05773290T
Other languages
English (en)
Inventor
Lisa Beavers
Serge Boulet
Terry Finn
Robert Gadski
William Hornback
Cynthia Jesudason
Richard Pickard
Freddie Stevens
Grant Vaught
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE432926T1 publication Critical patent/ATE432926T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT05773290T 2004-07-26 2005-07-14 Oxazolderivate als histamin-h3-rezeptor- wirkstoffe, deren herstellung und therapeutische verwendung ATE432926T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59119104P 2004-07-26 2004-07-26
PCT/US2005/024883 WO2006019833A1 (en) 2004-07-26 2005-07-14 Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses

Publications (1)

Publication Number Publication Date
ATE432926T1 true ATE432926T1 (de) 2009-06-15

Family

ID=35134220

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05773290T ATE432926T1 (de) 2004-07-26 2005-07-14 Oxazolderivate als histamin-h3-rezeptor- wirkstoffe, deren herstellung und therapeutische verwendung

Country Status (17)

Country Link
US (1) US7666871B2 (de)
EP (1) EP1786790B1 (de)
JP (1) JP4982367B2 (de)
CN (1) CN1989115B (de)
AT (1) ATE432926T1 (de)
AU (1) AU2005275183B2 (de)
BR (1) BRPI0513777A (de)
CA (1) CA2575081C (de)
CY (1) CY1109493T1 (de)
DE (1) DE602005014786D1 (de)
DK (1) DK1786790T3 (de)
ES (1) ES2325865T3 (de)
MX (1) MX2007001029A (de)
PL (1) PL1786790T3 (de)
PT (1) PT1786790E (de)
SI (1) SI1786790T1 (de)
WO (1) WO2006019833A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008301B2 (en) * 2004-04-01 2011-08-30 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
EP1848428A4 (de) 2005-02-18 2012-04-18 Neurogen Corp Thiazolamide, imidazolamide und verwandte analoga
AU2006228690A1 (en) 2005-03-31 2006-10-05 Ucb Pharma S.A. Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses
PL1954684T3 (pl) 2005-11-15 2014-10-31 Otsuka Pharma Co Ltd Związek oksazolowy i kompozycja farmaceutyczna
BRPI0709612A2 (pt) 2006-03-15 2011-07-19 Wyeth Corp composto de fórmula i; método para o tratamento de um distúrbio no sistema nervoso central relacionado ou afetado pelo receptor histamina-3 em um paciente que necessita deste tratamento; método para a inibição do receptor h3; composição farmacêutica; e processo para a preparação de um composto de fórmula i
CN101432261A (zh) 2006-05-19 2009-05-13 惠氏公司 作为组织胺-3拮抗剂的n-苯甲酰基-吡咯烷-3-基胺和n-苄基-吡咯烷-3-基胺
US20090215628A1 (en) * 2006-05-19 2009-08-27 Basf Se Benzoyl-Substituted Alanines
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
CA2693138A1 (en) * 2007-07-16 2009-01-22 Wyeth Llc Aminoalkylazole derivatives as histamine-3 antagonists
WO2009126782A1 (en) * 2008-04-11 2009-10-15 High Point Pharmaceuticals, Llc Histamine h3 receptor ligands
US8383829B2 (en) * 2008-04-15 2013-02-26 Konica Minolta Holdings, Inc. Electrochromic compound, electrode, and display element
SA110310332B1 (ar) * 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
SG186275A1 (en) 2010-07-06 2013-01-30 Astrazeneca Ab Therapeutic agents 976
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
AU2014208964B2 (en) 2013-01-23 2016-09-01 Astrazeneca Ab Chemical compounds
US9845291B2 (en) 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof
MA41562B1 (fr) 2015-06-03 2019-05-31 Bristol Myers Squibb Co Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
PL3319959T3 (pl) 2015-07-06 2022-02-14 Alkermes, Inc. Hetero-haloinhibitory deacetylazy histonowej
EP3319968A1 (de) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclische n-aminophenyl-amide als inhibitoren der histondeacetylase
WO2018132533A1 (en) 2017-01-11 2018-07-19 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
SI3664802T1 (sl) 2017-08-07 2022-10-28 Alkermes, Inc. Biciklični zaviralci histon deacetilaze

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3819037A1 (de) * 1988-06-04 1989-12-14 Hoechst Ag 2,4-disubstituierte oxazol-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als therapiemittel gegen krankheiten, die durch rhinoviren verursacht werden
KR100196356B1 (ko) * 1993-09-28 1999-06-15 오스카 아끼히꼬 당뇨병 치료제
AU3957600A (en) * 1999-04-26 2000-11-10 Boehringer Ingelheim International Gmbh Piperidyl-imidazole derivatives, their preparations and therapeutic uses
AU2002254114A1 (en) 2001-03-23 2002-10-08 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
CN1625554A (zh) 2002-02-01 2005-06-08 诺沃挪第克公司 氨基烷基－取代的氮杂环丁烷、吡咯烷、哌啶与氮杂环庚烷的酰胺
DE10259244A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh N-(Indolethyl-)cycloamin-Verbindungen
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
US7259262B2 (en) * 2003-10-24 2007-08-21 Hoffmann-La Roche Inc. Arylazole derivatives, their manufacture and use as pharmaceutical agents

Also Published As

Publication number Publication date
AU2005275183A1 (en) 2006-02-23
CY1109493T1 (el) 2014-08-13
DK1786790T3 (da) 2009-07-20
PL1786790T3 (pl) 2009-10-30
EP1786790B1 (de) 2009-06-03
AU2005275183B2 (en) 2011-03-17
WO2006019833A1 (en) 2006-02-23
CN1989115B (zh) 2012-03-21
MX2007001029A (es) 2007-04-12
JP4982367B2 (ja) 2012-07-25
CA2575081A1 (en) 2006-02-23
ES2325865T3 (es) 2009-09-22
PT1786790E (pt) 2009-08-18
JP2008507579A (ja) 2008-03-13
SI1786790T1 (sl) 2009-10-31
US7666871B2 (en) 2010-02-23
DE602005014786D1 (de) 2009-07-16
EP1786790A1 (de) 2007-05-23
CA2575081C (en) 2013-05-07
BRPI0513777A (pt) 2008-05-13
CN1989115A (zh) 2007-06-27
US20070197604A1 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
ATE432926T1 (de) Oxazolderivate als histamin-h3-rezeptor- wirkstoffe, deren herstellung und therapeutische verwendung
TWI262917B (en) 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same
NZ627750A (en) Carbamate compounds and of making and using same
ATE454372T1 (de) Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen
ATE537830T1 (de) Nicotinamid derivate und ihre verwendung als therapeutika
ECSP055633A (es) Nuevos derivados de benzoimidazolutiles como angentes antiproliferativos
RS51137B (sr) Derivat benzimidazola i njegova upotreba kao antagonista receptora aii
TW200716528A (en) Cyclopropanecarboxamide derivatives
ATE445609T1 (de) Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen
NO20064065L (no) Diaminopyrimidiner som P2X3 og P2X2/3 antagonister
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
RU2006147307A (ru) Производные 3-карбамоил-2-пиридона
ECSP024393A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular normal
MX2007008614A (es) Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r).
BRPI0506765A (pt) composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição
EA200970705A1 (ru) Новые фармацевтические композиции
PE20071177A1 (es) Derivados de 3,5-piridina como inhibidores de renina
ATE325796T1 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
MX2007005709A (es) Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida sustituidos.
GB0701366D0 (en) Novel pharmaceutical compositions
DE602005021150D1 (de) 3-substituierte pyridinderivate als h3-antagonisten
ECSP088829A (es) Derivados de bencimidazol 5-sulfonamida como ligandos del receptor cannabinoide 1 (cb1)
PE20060273A1 (es) Derivados de tetrahidroisoquinolilsulfonamidas como moduladores del receptor h3
JP2010513489A5 (de)
ES2197003A1 (es) Nuevos compuestos antagonistas de integrinas alfa.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1786790

Country of ref document: EP